Background
==========

Crohn's disease (CD) is a chronic inflammatory disease of unknown etiology. It is characterized by transmural inflammation of the bowel and may involve any section of the gastrointestinal (GI) tract. Stricturing and penetration are the 2 main complications, which markedly affect the patient's quality of life and increase the rate of surgery \[[@b1-medscimonit-25-8704]\]. Previous studies have shown that the occurrence of complications increases with time, and earlier use of thiopurines and anti-tumor necrosis factor-α monoclonal antibody reduces the need for surgery \[[@b1-medscimonit-25-8704],[@b2-medscimonit-25-8704]\]. The current aim of treatment is to minimize complications and reduce the need for surgery. However, diagnosing CD is difficult because there are no specific symptoms or criteria, and much depends on the experience of the gastroenterologist in differentiating CD from other conditions, such as autoimmune disorders, infections, carcinomas, and drug use. Moreover, diagnosis is more difficult in the early stage of disease without complications (e.g., non-stricturing, non-penetrating behavior, B1), especially when only the small bowel (SB) is involved. This is because for many years the part of the SB beyond the duodenum and proximal to the terminal ileum could not be viewed endoscopically and the sensitivity of SB radiography (SBR) is low \[[@b3-medscimonit-25-8704]\]. In recent years, advanced modalities for investigation of SB disease have become available. At our medical center, SB capsule endoscopy (SBCE) (since 2003), balloon-assisted enteroscopy (BAE) (including single-balloon enteroscopy and double-balloon enteroscopy) (since 2006), computed tomography enterography (CTE) (since 2006), and magnetic resonance imaging enterography (MRE) (since 2010) are now routinely used for detection of SB disease. Carbon dioxide insufflation was introduced in 2011, which improved both the intubation depth and total single-balloon enteroscopy rate \[[@b4-medscimonit-25-8704]\], and possibly allowed visualization of more SB lesions. Theoretically, these modalities should be helpful in the early detection of SB disease without complications because they are highly sensitive \[[@b3-medscimonit-25-8704],[@b5-medscimonit-25-8704]\]. To confirm this hypothesis, we retrospectively analyzed patients with newly diagnosed CD at our medical center between 2005 and 2014, focusing on detection and diagnosis of SB CD.

Material and Methods
====================

Patients
--------

The Research Ethics Committee of Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University approved this study.

Patients diagnosed with CD and whose complete medical data were available were included and classified according to the Montreal system \[[@b6-medscimonit-25-8704]\]. Diagnosis of CD was based on clinical, endoscopic, histopathological, and radiological findings \[[@b7-medscimonit-25-8704]\]. Disease location was defined by the maximal extent, including the segmental intestine previously removed surgically. Stricturing (B2) and penetrating (B3) complications had been detected by radiology, endoscopy, or surgery, according to the medical records. If both stricturing and penetrating complications were detected at the time of diagnosis, the complications were classified as penetrating. Patients were excluded if: (1) they could not be classified according to the Montreal system based on their medical data, or (2) they were diagnosed with CD after CD was suspected for 5 years or more. Demographic characteristics, clinical presentations, and modalities used to detect SB CD were analyzed.

Patients were divided into two 5-year periods -- 2005--2009 and 2010--2014 -- based on the year of diagnosis.

Statistical analysis
--------------------

Variables are presented as numbers and percentages. The chi-square test or Fisher's exact test was used to compare categorical variables between groups. The Mann-Whitney *U* test was used to analyze the duration from symptom onset to lesion detection. A two-sided *P* value of ≤0.05 indicated statistical significance.

Results
=======

Complications were not reduced by use of advanced modalities
------------------------------------------------------------

Between January 2005 and December 2014, 511 patients were admitted and newly diagnosed with CD at our medical center; of these, 40 (7.8%) were excluded because they could not be classified according to the Montreal system. Thus, a total of 471 patients with a male-to-female ratio of 1.71: 1 were included. The median age at diagnosis was 30 years (IQR \[interquartile range\], 23--40 years). No significant differences were found in the rates of stricturing and penetrating complications between the periods of 2005--2009 and 2010--2014 ([Table 1](#t1-medscimonit-25-8704){ref-type="table"}). Analysis of the modalities used to investigate the GI tract showed the following results: significantly fewer patients were diagnosed by surgery, and significantly more patients underwent CT, CTE, MRE, and BAE instead of SBR in 2010--2014 ([Table 2](#t2-medscimonit-25-8704){ref-type="table"}). The rate at which B1 disease was detected was not higher with the use of these advanced modalities in 2010--2014 (*P*=0.269) (46.2%) than that in 2005--2009 (51.6%). However, significantly more patients had perianal disease in 2010--2014 than in 2005--2009, and the occurrence of stricturing and penetrating complications was significantly lower in the patients with perianal disease than in those without perianal disease ([Table 3](#t3-medscimonit-25-8704){ref-type="table"}).

Clinical characteristics of SB CD
---------------------------------

Stricturing disease has been reported as a complication of small intestinal disease \[[@b8-medscimonit-25-8704]\]. Patients with SB involvement were divided into 2 groups: the SB only group and the SB+colon group ([Table 4](#t4-medscimonit-25-8704){ref-type="table"}). Obstruction occurred in 24 (20.5%) patients in the SB only group, a rate that was significantly higher than that in the SB+colon group (28 \[9.4%\]; *P*=0.002). The duration from symptom onset to lesion detection was significantly longer in the SB only group (median, 12 months; IQR, 3--48 months) than that in the SB+colon group (median, 5 months; IQR, 0--24 months) (*P*\<0.001).

Demographic characteristics and clinical presentations were compared ([Table 5](#t5-medscimonit-25-8704){ref-type="table"}). Significantly more patients in the SB only group had anemia (44.4%) and nausea/vomiting (24.8%). Obstruction was significantly more common in patients with nausea/vomiting (69.0%) than in those without these symptoms (45.5%) (*P*=0.028). Abdominal pain was the most common symptom in both groups, followed by GI bleeding; in fact, occult bleeding, which was only positively detected using a fecal occult blood test without visible blood loss, was considerably more common than overt bleeding. In the SB only group, 16 (30.8%) patients with anemia had positive results in the fecal occult blood test. A total of 110 (94.0%) patients had GI bleeding and anemia.

Modalities for investigation of SB involvement
----------------------------------------------

The modalities used to investigate SB involvement were compared, showing that significantly more patients in the SB only group underwent gastroscopy, CT, SBCE, and BAE, while significantly more patients in the SB+colon group underwent colonoscopy and CTE ([Table 6](#t6-medscimonit-25-8704){ref-type="table"}). In the SB only group, lesions were first detected by colonoscopy in 20.4% patients, by CT in 21.3% patients, and by SBCE in 21.3% patients. In the SB+colon group, lesions were first detected by colonoscopy in 39.6% of patients. GI lesions were detected using other modalities in no more than 10% of patients in both groups.

In a subsequent analysis, we examined the use of different modalities for initial detection and diagnosis of SB CD. Ileal involvement was first detected by colonoscopy and CTE in significantly more patients with L3 and L3+L4 involvement than in those with L1 and L1+L4 involvement. In contrast, it was detected by CT and SBCE in significantly more patients with L1 and L1+L4 involvement than in those with L3 and L3+L4 involvement ([Table 7](#t7-medscimonit-25-8704){ref-type="table"}). The diagnosis of L1 and L1+L4 involvement was made from BAE, colonoscopy, and SBCE findings; in particular, BAE diagnosed more patients than the other modalities did ([Figure 1](#f1-medscimonit-25-8704){ref-type="fig"}).

Upper GI CD was detected using different modalities, and no particular modality was best for this purpose ([Table 8](#t8-medscimonit-25-8704){ref-type="table"}), even though SBCE revealed L4 and L1+L4 involvement (26.8%) in significantly more patients than the number in which it revealed L2+L4 and L3+L4 involvement (7.3%) (*P*=0.001). Only 9 patients were diagnosed with L4 involvement.

Discussion
==========

Prospective studies have shown that advanced modalities have better sensitivity than conventional SBR for detection of SB involvement in CD \[[@b9-medscimonit-25-8704]--[@b11-medscimonit-25-8704]\]. Therefore, it is to be expected that the rates at which ileal CD and upper GI disease are detected in the early stage will be higher with the use of these modalities. Our findings revealed that these advanced modalities did not detect higher rates of B1 disease ([Table 4](#t4-medscimonit-25-8704){ref-type="table"}), and the rate at which stricture was detected at diagnosis was not lower than that with the older modalities. Since the probability of a stricturing complication increases with disease duration and occurrence of a stricturing complication is associated with SB involvement and the absence of colonic involvement \[[@b12-medscimonit-25-8704]\], we detected the duration from symptom onset to lesion detection and showed significantly longer duration in the SB only group than in the SB+colon group, which suggested that shorter the duration would decrease the rate of stricturing complication.

In the SB+colon group, colonoscopy first detected colonic lesions in 82.7% of patients; in the SB only group, no one modality was best, although colonoscopy is recommended as the best modality to detect ileal-involved diseases \[[@b13-medscimonit-25-8704]\]. Colonoscopy first detected significantly more ileal lesions of L3 and L3+L4 than that of L1 and L1+L4 (39.6% *vs.* 20.4%) ([Table 7](#t7-medscimonit-25-8704){ref-type="table"}), which was much lower than shown in a prospective study (80.0%) \[[@b14-medscimonit-25-8704]\]. We think the difference arose from the fact that the previous studies did not separate L3 from L1 disease. Although BAE is not recommended as the first-line procedure for SB CD evaluation \[[@b13-medscimonit-25-8704]\], since the procedure is complex and has a low rate of completion, which limits its widespread use, the percentage of patients who underwent BAE (80.3%) was similar to that of colonoscopy (86.3%). Frequent use of BAE also suggested the limited role of colonoscopy.

SBCE is recommended as the initial modality for investigating SB in the absence of obstructive symptoms or stenosis when gastroscopy and colonoscopy are inconclusive \[[@b14-medscimonit-25-8704]\]. It is reported SBCE is more sensitive than radiologic imaging (CTE or MRE) for the detection of proximal SB disease, and it detected significantly more cases of isolated upper GI disease in white patients \[[@b15-medscimonit-25-8704]--[@b18-medscimonit-25-8704]\]. In our study, it was the only modality that was best for detecting both L1 ([Table 7](#t7-medscimonit-25-8704){ref-type="table"}) and L4 ([Table 8](#t8-medscimonit-25-8704){ref-type="table"}) disease. In the SB only group, significantly more patients underwent SBCE than in the SB+colon group, even though significantly more patients had obstructions. However, SBCE first detected SB lesions in 21.3% of patients, a rate similar to that of colonoscopy (20.4%) and CT (21.3%), while fewer patients underwent SBCE (28.2%) compared to colonoscopy (86.3%) or CT (38.5%), which may be partly explained by the high prevalence of the stricturing complication. Another possible reason was that the examination of SBCE was vastly more expensive than colonoscopy and CT. We believe that in the future, an increasing number of patients will accept SBCE because health insurance covers the examination in China. CTE or MRE, as a noninvasive and less sensitive examinations, can be used to evaluate intestinal penetration/obstruction before SBCE \[[@b19-medscimonit-25-8704]\].

In investigating SB using SBCE before the occurrence of stricture, we tried to find the alarming clinical manifestation of SB CD. Abdominal pain was the most common presentation, and use further examinations could not be decided on from subjective symptoms. In the SB only group, significantly more patients presented with nausea and vomiting, which were associated with obstruction complication. Further, significantly more patients were found to have anemia, and GI bleeding (30.8%) was a common cause. A total of 63.2% of patients had GI bleeding, including 21.4% patients with overt GI bleeding, and they probably did not know how long they had chronic occult bleeding before developing overt bleeding. In our study, 94.0% of patients with SB CD had GI bleeding and anemia, which were indications for further GI examinations. Our hypothesis is that if the fecal occult blood test and routine blood test, which are the 2 cheapest and simplest examinations available in every hospital, had been performed in patients who experienced abdominal pain and other GI manifestations, GI bleeding or anemia would have been discovered, and, according to the guideline, SB lesions could have been detected at the early stage of CD. In recent years, fecal calprotectin and lactoferrin were increasingly being used as markers of active GI inflammation, but they are not correlated with ileal disease \[[@b20-medscimonit-25-8704]\]. In Kelvin's population-based study \[[@b12-medscimonit-25-8704]\], B1 disease was detected in 81.4% of patients and L1 disease was detected in 42.5% of patients. The lower rate of complications in this previous study could be explained by earlier disease presentation, better awareness, and better access to healthcare services. We hope our findings will improve the awareness of clinicians at a time in which the incidence and prevalence of CD are increasing in China.

This study has certain limitations. First, it was a retrospective study and some factors associated with CD status were not evaluated. Because only inpatients were enrolled, selection bias could not be ruled out; these patients were likely to have higher rates of complications and more aggressive clinical courses than outpatients (since patients with probable CD needed hospitalization during the 5-year follow-up). Second, the SB only group sample size was small, and all patients were from a single institution (diagnostic modalities at other medical centers may be different). Third, the study spanned a 10-year period, over which different doctors were involved in diagnosis and treatment.

Conclusions
===========

Our results revealed that advanced modalities did not detect a higher rate of B1 disease than older modalities, possibly because the duration from symptom onset to lesion detection was significantly longer in patients with SB CD. Our results also revealed that 94.0% of patients with SB CD had GI bleeding and anemia. Our hypothesis is that the fecal occult blood test and routine blood test should be administered to patients with abdominal pain and other GI manifestations. Once the patients were found to have GI bleeding or anemia, they would be further examined according to the guideline and SBCE would be used in the early stage of SB CD. Our hypothesis needs to be confirmed a large prospective clinical trial.

**Source of support:** Departmental sources

![Modalities used for diagnosis of small-bowel Crohn's disease. SBCE -- small-bowel capsule endoscopy; BAE, balloon-assisted enteroscopy.](medscimonit-25-8704-g001){#f1-medscimonit-25-8704}

###### 

Clinical characteristics of newly diagnosed patients: number (percentage).

                             Total (n=471)   2005--2009 (n=155)   2010--2014 (n=316)   *P* value
  -------------------------- --------------- -------------------- -------------------- -----------
  Age (years) at diagnosis                                                             
   A1 (≤16)                  25 (5.3%)       9 (5.8%)             16 (5.1%)            0.375
   A2 (17--40)               336 (71.3%)     102 (65.8%)          234 (74.1%)          0.063
   A3 (\>40)                 110 (23.4%)     44 (28.4%)           66 (20.9%)           0.071
  Location                                                                             
   L1 (Terminal ileum)       60 (12.7%)      20 (12.9%)           41 (13.0%)           0.983
   L2 (Colon)                54 (11.5%)      17 (11.0%)           37 (11.7%)           0.812
   L3 (Ileocolon)            204 (43.3%)     71 (45.8%)           133 (42.1%)          0.444
   L4 (Upper GI)             9 (1.9%)        3 (1.9%)             6 (1.9%)             1.000
   L1+L4                     47 (10.0%)      14 (9.0%)            33 (10.4%)           0.631
   L2+L4                     6 (1.3%)        3 (1.9%)             3 (0.9%)             0.400
   L3+L4                     90 (19.1%)      27 (17.4%)           63 (19.9%)           0.514
  Behavior                                                                             
   B1 (Non-str/non-pen)      226 (48.0%)     80 (51.6%)           146 (46.2%)          0.269
   B2 (Stricturing)          181 (38.4%)     54 (34.8%)           127 (40.2%)          0.262
   B3 (Penetrating)          64 (13.6%)      21 (13.5%)           43 (13.6%)           0.986
  Perianal disease           102 (21.7%)     23 (14.8%)           79 (25.0%)           0.012

GI -- gastrointestinal; non-str -- non-stricturing; non-pen -- non-penetrating.

###### 

Modalities used to investigate the gastrointestinal tract: number (percentage).

                Total (n=471)   2005--2009 (n=155)   2010--2014 (n=316)   *P* value
  ------------- --------------- -------------------- -------------------- -----------
  Gastroscopy   167 (35.5%)     53 (34.2%)           114 (36.1%)          0.688
  Colonoscopy   456 (96.8%)     152 (98.1%)          304 (96.2%)          0.280
  SBR           97 (20.6%)      68 (43.9%)           29 (9.2%)            0.000
  CT            124 (26.3%)     26 (16.8%)           98 (31.0%)           0.001
  CTE           280 (59.4%)     60 (38.7%)           220 (69.6%)          0.000
  MRI           74 (15.7%)      22 (14.2%)           52 (16.5%)           0.526
  MRE           41 (8.7%)       1 (0.6%)             40 (12.7%)           0.000
  SBCE          43 (9.1%)       17 (11.0%)           26 (8.2%)            0.332
  BAE           196 (41.6%)     53 (34.2%)           143 (45.3%)          0.022
  Surgery       38 (8.1%)       26 (16.8%)           12 (3.8%)            0.000
  PET           13 (2.8%)       1 (0.6%)             12 (3.8%)            0.063

SBR -- small-bowel radiography, including small-bowel follow-through and enteroclysis; CT -- computed tomography; CTE -- computed tomography enterography; MRI -- magnetic resonance imaging; MRE -- magnetic resonance imaging enterography; SBCE -- small-bowel capsule endoscopy; BAE -- balloon-assisted enteroscopy; PET -- positron emission tomography.

###### 

Behavior of CD in patients with or without perianal disease: number (percentage).

                Patients with perianal disease (n=102)   Patients without perianal disease (n=369)   *P* value
  ------------- ---------------------------------------- ------------------------------------------- -----------
  Behavior                                                                                           0.000
   B1 (n=226)   75 (33.2%)                               151 (66.8%)                                 
   B2 (n=181)   21 (11.6%)                               160 (88.4%)                                 
   B3 (n=64)    6 (9.4%)                                 58 (90.6%)                                  

###### 

Clinical characteristics of groups A and B: number (percentage).

          SB only group (n = 117)   SB+colon group (n = 300)   P value                                                                     
  ------- ------------------------- -------------------------- ------------ ---------- ------------- ---------- ------------- ------------ -------
  B1      43 (36.8%)                22 (18.8%)                 16 (13.7%)   5 (4.3%)   152 (50.7%)   4 (1.3%)   104 (34.7%)   44 (14.7%)   0.011
  B2      61 (52.1%)                29 (24.8%)                 29 (24.8%)   3 (2.6%)   101 (33.7%)   2 (0.7%)   69 (23.0%)    30 (10.0%)   0.001
  B3      13 (11.1%)                9 (7.7%)                   3 (2.6%)     1 (0.9%)   47 (15.7%)    0 (0.0%)   30 (10.0%)    17 (5.7%)    0.234
  Total                             60 (51.3%)                 48 (41.0%)   9 (7.7%)                 6 (2.0%)   203 (67.7%)   91 (30.0%)   

GI -- gastrointestinal; B1 -- non-stricturing/non-penetrating; B2 -- stricturing; B3 -- penetrating.

###### 

Demographic characteristics and clinical presentations.

                              SB only group (n=117)   SB+colon group (n=300)   *P* value
  --------------------------- ----------------------- ------------------------ -----------
  Sex                                                                          0.440
   Male                       42 (35.9%)              120 (40.0%)              
   Female                     75 (64.1%)              180 (60.0%)              
  Smoking history                                                              0.271
   Non-smoker                 109 (93.2%)             269 (89.7%)              
   Ever smoker                8 (6.8%)                31 (10.3%)               
  Gastrointestinal symptoms                                                    
   Abdominal pain             87 (74.4%)              219 (73.0%)              0.778
   Diarrhea                   37 (31.6%)              169 (56.3%)              0.000
  Abdominal mass              5 (4.3%)                16 (5.3%)                0.657
   GI bleeding                74 (63.2%)              217 (72.3%)              0.924
  Overt bleeding              25 (21.4%)              72 (24.0%)               0.568
   Occult bleeding            49 (41.9%)              145 (48.3%)              0.235
  Nausea and vomiting         29 (24.8%)              41 (13.7%)               0.006
   Perianal disease           12 (10.3%)              76 (25.3%)               0.001
  Systemic presentation                                                        
   Fever (\>37.8°C)           59 (50.4%)              100 (33.3%)              0.177
   Weight loss                62 (53.3%)              133 (44.3%)              0.000
   Anorexia                   9 (7.7%)                13 (4.3%)                0.168
   Anemia                     52 (44.4%)              88 (29.3%)               0.003
  Extraintestinal symptoms    3 (2.6%)                32 (10.7%)               0.007

GI -- gastrointestinal. Occult bleeding, only fecal occult blood test was positive.

###### 

Modalities used for SB investigation: number (percentage).

                Total (n=471)   SB only group (n=117)   SB+colon group (n=300)   *P* value
  ------------- --------------- ----------------------- ------------------------ -----------
  Gastroscopy   157 (37.6%)     69 (59.0%)              88 (29.3%)               0.000
  Colonoscopy   396 (95.0%)     101 (86.3%)             295 (98.3%)              0.000
  SBR           93 (22.3%)      30 (25.6%)              63 (21.0%)               0.306
  CT            113 (27.1%)     45 (38.5%)              68 (22.7%)               0.001
  CTE           241 (57.8%)     54 (46.2%)              187 (62.3%)              0.003
  MRE           39 (9.4%)       10 (8.6%)               29 (9.7%)                0.724
  SBCE          43 (10.3%)      26 (22.2%)              17 (5.7%)                0.000
  BAE           192 (46.0%)     94 (80.3%)              98 (32.7%)               0.000
  Surgery       38 (9.1%)       13 (11.1%)              31 (10.3%)               0.376
  PET           12 (2.9%)       5 (4.3%)                7 (2.3%)                 0.287

SBR -- small-bowel radiography, including small-bowel follow-through and enteroclysis; CT -- computed tomography; CTE -- computed tomography enterography; MRE -- magnetic resonance imaging enterography; SBCE -- small-bowel capsule endoscopy; BAE -- balloon-assisted enteroscopy; PET -- positron emission tomography.

###### 

Modalities that detected ileal lesions first: number (percentage).

                Total (n=108)   L1 (n=61)    L1+L4 (n=47)   Total (n=293)    L3 (n=203)   L3+L4 (n=90)   *P* value
  ------------- --------------- ------------ -------------- ---------------- ------------ -------------- -----------
  Colonoscopy   22 (20.4%)^a^   12 (19.7%)   10 (21.3%)     116 (39.6%)^a^   81 (40.0%)   35 (38.9%)     0.000^a^
  SBR           7 (6.5%)        5 (8.2%)     2 (4.3%)       32 (10.9%)       22 (10.8%)   10 (11.1%)     
  CT            23 (21.3%)^b^   16 (26.2%)   7 (14.9%)      16 (5.5%)^b^     13 (6.4%)    3 (3.3%)       0.017^b^
  CTE           14 (13.0%)^c^   7 (11.5%)    7 (14.9%)      70 (23.9%)^c^    51 (25.1%)   19 (21.1%)     0.000^c^
  MRI           0 (0.0%)        0 (0.0%)     0 (0.0%)       2 (0.7%)         1 (0.5%)     1 (1.1%)       
  MRE           0 (0.0%)        0 (0.0%)     0 (0.0%)       13 (4.4%)        9 (4.4%)     4 (4.4%)       
  SBCE          23 (21.3%)^d^   9 (14.8%)    14 (29.8%)     5 (1.7%)^d^      1 (0.5%)     4 (4.4%)       0.000^d^
  BAE           11 (10.2%)      7 (11.5%)    4 (8.5%)       23 (7.9%)        14 (6.9%)    9 (10.0%)      
  Surgery       7 (6.5%)        5 (8.2%)     2 (4.3%)       15 (5.1%)        11 (5.4%)    4 (4.4%)       
  PET           1 (0.9%)        0 (0.0%)     1 (2.1%)       1 (0.3%)         0 (0.0%)     1 (1.1%)       

SBR -- small-bowel radiography, including small-bowel follow-through and enteroclysis; CT -- computed tomography; CTE -- computed tomography enterography; MRI -- magnetic resonance imaging; MRE -- magnetic resonance imaging enterography; SBCE -- small-bowel capsule endoscopy; BAE -- balloon-assisted enteroscopy; PET -- positron emission tomography.

###### 

Modalities that were the first to detect upper gastrointestinal disease: number (percentage).

                Total (n=56)   L4 (n=9)    L1+L4 (n=47)   Total (n=96)   L3+L4 (n=90)   L2+L4 (n=6)   *P* value
  ------------- -------------- ----------- -------------- -------------- -------------- ------------- -----------
  Gastroscopy   9 (16.1%)      1 (11.1%)   8 (17.0%)      60 (0.0%)      0 (0.0%)       0 (0.0%)      
  Colonoscopy   0 (0.0%)       0 (0.0%)    0 (0.0%)       18 (18.8%)     17 (18.9%)     1 (16.7%)     
  SBR           6 (10.7%)      2 (22.2%)   4 (8.5%)       19 (19.8%)     16 (17.8%)     3 (50.0%)     
  **CT**        5 (9.0%)       3 (33.3%)   2 (4.3%)       6 (6.3%)       5 (5.6%)       1 (16.7%)     
  MRI           0 (0.0%)       0 (0.0%)    0 (0.0%)       1 (1.0%)       1 (1.1%)       0 (0.0%)      
  CTE           15 (26.8%)     1 (11.1%)   14 (29.8%)     27 (28.1%)     27 (30.0%)     0 (0.0%)      
  MRE           1 (1.8%)       0 (0.0%)    1 (2.1%)       6 (6.3%)       5 (5.6%)       1 (16.7%)     
  SBCE          15 (26.8%)e    1 (11.1%)   14 (29.8%)     7 (7.3%)e      7 (7.8%)       0 (0.0%)      0.001^e^
  BAE           3 (5.4%)       1 (11.1%)   2 (4.3%)       5 (5.2%)       5 (5.6%)       0 (0.0%)      
  Surgery       1 (1.8%)       0 (0.0%)    1 (2.1%)       6 (6.3%)       6 (6.7%)       0 (0.0%)      
  PET           1 (1.8%)       0 (0.0%)    1 (2.1%)       1 (1.0%)       1 (1.1%)       0 (0.0%)      

SBR -- small-bowel radiography, including small-bowel follow-through and enteroclysis; CT -- computed tomography; CTE -- computed tomography enterography; MRE -- magnetic resonance imaging enterography; SBCE -- small-bowel capsule endoscopy; BAE -- balloon-assisted enteroscopy; PET -- positron emission tomography.
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